生物功能晶片(Organs-On-Chips)的全球市场规模:各终端用户，各用途，各类型，各地区，范围及预测

晶片器官市场规模及预测

2024 年，晶片器官市场规模为 921.6 亿美元，预计 2024 年至 2031 年复合年增长率为 10.56%，到 ​​2031 年将达到 1915 亿美元。器官晶片是一种微流体装置，可以在微型尺度上再现人体器官的结构和功能。这些晶片包含模拟器官生理环境的活体人体细胞，使研究人员能够在受控环境中研究器官功能、疾病机制和药物反应。透过提供比传统细胞培养或动物实验更准确的模型，器官晶片为人类生物学提供了宝贵的见解。

生物功能晶片（Organs-On-Chips）的应用范围广泛，正在对各个领域产生影响。它主要用于药物开发和毒性测试，使製药公司能够评估新化合物对人体组织的影响，而无需仅依赖动物模型。

此外，这些设备还可用于研究疾病过程，使研究人员能够在更生理相关的背景下研究癌症、心血管疾病和神经退化性疾病等疾病。

全球器官晶片市场动态

塑造全球晶片器官市场的主要市场动态

主要驱动因素

微加工的进展：

微加工技术的创新将增强晶片上器官的设计和功能，提高其准确性和适用性。根据美国国家标准与技术研究院 (NIST) 2024 年 2 月发布的报告，2020 年至 2023 年间，生物医学应用微加工研究的投资增加了 35%。

对个人化医疗的需求不断增加：

向个人化医疗的转变正在推动人们对用于药物测试和疾病建模的器官晶片的兴趣，以提供客製化的治疗解决方案。 2024年1月，美国食品药物管理局（FDA）报告称，2023年个人化医疗的核准数量较前一年增加28%。

监理支援：

药物开发和毒性测试监管机构对晶片器官的认可度不断提高，正在加速其在製药和生物技术行业的采用。例如，2024 年 1 月，欧洲药品管理局 (EMA) 发布了在临床前药物测试中使用器官晶片的新指南，显示监管过程中对该技术的接受度不断提高。

主要问题

开发成本高：

器官晶片所需的复杂製造流程和技术可能会导致巨大的研发成本。

技术限制：

目前的模型可能无法完全再现人体器官的复杂性，限制了它们在某些研究领域的可靠性和适用性。

监理挑战：

在药物测试中推动器官晶片的接受和标准化不断发展的监管环境将成为广泛采用的障碍。

主要趋势

与人工智慧和机器学习整合：

引入人工智慧技术将增强数据分析和预测建模，提高药物测试和疾病研究中器官晶片系统的准确性。根据美国国立卫生研究院 (NIH) 2024 年 1 月发布的报告，2021 年至 2023 年间，人工智慧与晶片器官系统结合使用将增加 58%。

多重器官模型的扩展：

人们对多器官晶片的兴趣日益浓厚，可以实现更复杂的相互作用并更好地模拟人体生理学，从而推进药物疗效和安全性的评估。例如，2024 年 1 月，TissUse GmbH 宣布推出 "晶片人体" 平台，该平台允许多达 10 个不同的器官模型与一个微流体设备连接。

关注疾病模型：

对特定疾病模型的需求不断增长，正在推动器官晶片的创新，并促进对癌症、心血管疾病和神经退化性疾病等疾病的研究。例如，2024 年 2 月，Emulate, Inc. 宣布与阿兹海默症协会合作开发一款专门用于模拟神经退化性疾病的 "大脑晶片" 。

目录

第1章 全球生物功能晶片(Organs-On-Chips)市场简介

• 市场概要
• 调查范围
• 前提条件

第2章 摘要整理

第3章 VERIFIED MARKET RESEARCH的调查手法

• 资料探勘
• 检验
• 主要采访
• 资料来源一览
• 市场魅力

第4章 全球生物功能晶片(Organs-On-Chips)市场展望

• 概要
• 市场动态
  • 促进因素
  • 阻碍因素
  • 机会
• 波特的五力分析
• 价值链分析

第5章 生物功能晶片(Organs-On-Chips)的全球市场:各类型

• 心臟晶载
• 人晶载
• 肠晶载
• 肾臟晶载
• 晶载肝臟
• 肺晶载

第6章 生物功能晶片(Organs-On-Chips)全球市场:各用途

• 药物研发
• 毒理学研究
• 生理模式
• 其他的用途

第7章 生物功能晶片(Organs-On-Chips)全球市场:各终端用户

• 製药及生物科技企业
• 学术机构
• 研究机关

第8章 生物功能晶片(Organs-On-Chips)的全球市场:各地区

• 概要
• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 全球其他地区
  • 南美
  • 中东·非洲

第9章 全球生物功能晶片(Organs-On-Chips)市场竞争情形

• 概要
• 各公司的市场排行榜
• 主要的开发策略
• ACE矩阵

第10章 企业简介

• BiomimX SRL
• Elveflow
• Hesperos
• Altis Biosystems
• Nortis Inc.
• AxoSim
• Bi/ond
• InSphero
• Emulate Inc.
• Allevi Inc.
• MIMETAS BV
• Netri
• Valo Health(Tara Biosystems Inc.)
• TissUse GmbH

第11章 主要发展

• 产品的上市/开发
• 合併和收购
• 事业扩大
• 伙伴关係和合作

第12章 附录

• 相关调查

Organs-On-Chips Market Size And Forecast

Organs-On-Chips Market size was valued at USD 92.16 Billion in 2024 and is projected to reach USD 191.5 Billion by 2031, growing at a CAGR of 10.56% from 2024 to 2031. Organs-on-chips are microfluidic devices that replicate the structure and function of human organs at a miniature scale. These chips contain living human cells arranged in a way that mimics the physiological environment of the organs they represent, enabling researchers to study organ functions, disease mechanisms, and drug responses in a controlled setting. By providing a more accurate model than traditional cell culture or animal testing, organs-on-chips offer valuable insights into human biology.

The applications of organs-on-chips are diverse and impactful across various fields. They are primarily used in drug development and toxicity testing, allowing pharmaceutical companies to assess the effects of new compounds on human tissues without relying solely on animal models.

Additionally, these devices can be used to study disease processes, enabling researchers to investigate conditions like cancer, cardiovascular diseases, and neurodegenerative disorders in a more physiologically relevant context.

Global Organs-On-Chips Market Dynamics

The key market dynamics that are shaping the global organs-on-chips market include:

Key Drivers

Advancements in Microfabrication:

Innovations in microfabrication technologies enhance the design and functionality of organs-on-chips, improving their accuracy and applicability. According to a report by the National Institute of Standards and Technology (NIST) published in February 2024, investments in microfabrication research for biomedical applications increased by 35% between 2020 and 2023.

Rising Demand for Personalized Medicine:

The shift towards personalized medicine fuels interest in organs-on-chips for drug testing and disease modeling, providing tailored therapeutic solutions. The U.S. Food and Drug Administration (FDA) reported in January 2024 that the number of personalized medicine approvals increased by 28% in 2023 compared to the previous year.

Regulatory Support:

Increasing recognition of organs-on-chips by regulatory bodies for drug development and toxicity testing accelerates adoption in pharmaceutical and biotech industries. For instance, in January 2024, the European Medicines Agency (EMA) released new guidelines for the use of organs-on-chips in preclinical drug testing, signaling growing acceptance of this technology in regulatory processes.

Key Challenges:

High Development Costs:

The complex manufacturing processes and technology required for organs-on-chips can lead to significant research and development expenses.

Technical Limitations:

Current models may not fully replicate the complexity of human organs, limiting their reliability and applicability in certain research areas.

Regulatory Challenges:

Navigating the evolving regulatory landscape for acceptance and standardization of organs-on-chips in drug testing poses hurdles for widespread adoption.

Key Trends

Integration with AI and Machine Learning:

The incorporation of AI technologies enhances data analysis and predictive modeling, improving the accuracy of organ-on-chip systems in drug testing and disease research. According to a report by the National Institutes of Health (NIH) published in January 2024, the use of AI in conjunction with organ-on-chip systems increased by 58% between 2021 and 2023.

Expansion of Multi-Organ Models:

Increasing interest in multi-organ chips allows for more complex interactions and better simulation of human physiology, advancing drug efficacy and safety assessments. For instance, in January 2024, TissUse GmbH unveiled their "Human-on-a-Chip" platform, capable of connecting up to ten different organ models in a single microfluidic device.

Focus on Disease Modeling:

Growing demand for disease-specific models drives innovation in organs-on-chips, facilitating research on conditions like cancer, cardiovascular diseases, and neurodegenerative disorders. For instance, in February 2024, Emulate, Inc. announced a collaboration with the Alzheimer's Association to develop a "Brain-Chip" specifically designed to model neurodegenerative disorders.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Organs-On-Chips Market Regional Analysis

Here is a more detailed regional analysis of the global organs-on-chips market:

North America

North America is dominating the organs-on-Chips market, driven by substantial investments in research and development, a robust biotechnology sector, and supportive regulatory frameworks. The U.S. National Institutes of Health (NIH) reported allocating USD 89 Million in fiscal year 2023 to support research on microphysiological systems, including organs-on-chips, highlighting the region's commitment to advancing this technology. This significant funding has accelerated the development and adoption of organs-on-chips across pharmaceutical companies, academic institutions, and research organizations in North America.

The region's dominance is further solidified by the presence of leading market players and a growing emphasis on reducing animal testing in drug development. According to the U.S. Food and Drug Administration (FDA), the average cost to develop a new drug exceeds USD 2.6 Billion, with a significant portion attributed to preclinical testing. Organs-on-chips technology offers a promising solution to reduce these costs and improve the efficiency of drug discovery processes, driving its adoption across the pharmaceutical industry in North America.

Recent developments in the market have seen key players introducing innovative solutions and expanding their product offerings. In February 2024, Emulate Inc. announced the launch of a new multi-organ chip platform capable of simulating complex organ interactions, aimed at enhancing drug toxicity studies. Additionally, CN Bio Innovations reported in December 2023 a collaborative agreement with a major U.S. pharmaceutical company to develop custom organ-on-chip models for respiratory disease research, demonstrating the growing industry adoption of this technology in North America.

Asia Pacific

The Asia Pacific region is experiencing rapid growth in the organs-on-chips market, driven by increasing investment in life sciences research, rising demand for personalized medicine, and government initiatives to promote innovative healthcare technologies.

According to the Japan Agency for Medical Research and Development (AMED), the country invested approximately 146 billion yen (USD 1.3 Billion) in fiscal year 2022 for medical research and development, with a significant portion allocated to advanced biotechnologies like organs-on-chips. This substantial funding has catalyzed research activities and collaborations between academic institutions and industry players, fostering the adoption of organs-on-chips technology across the region.

The market's growth is further propelled by the region's large and diverse patient population, which presents unique opportunities for drug discovery and personalized medicine applications. China's National Medical Products Administration (NMPA) reported in 2023 that the country had over 5,000 new drug applications under review, highlighting the immense potential for organs-on-chips technology to streamline the drug development process. This has led to increased collaboration between local pharmaceutical companies and organs-on-chips developers to create more efficient and cost-effective drug screening methods.

Global Organs-On-Chips Market: Segmentation Analysis

The Global Organs-On-Chips Market is segmented on the basis of End-User, Application, Type, And Geography.

Organs-On-Chips Market, By End-User

• Pharmaceutical and biotechnology companies
• Academic
• Research institutes

Based on the End-User, the Global Organs-On-Chips Market is segmented into Pharmaceutical and biotechnology companies, Academic, Research institutes. In the organs-on-chips market, pharmaceutical and biotechnology companies are the dominant end users, leveraging these technologies to enhance drug development processes and improve safety assessments. Meanwhile, the academic segment is experiencing rapid growth, fueled by increasing research initiatives and funding aimed at understanding complex biological systems. This trend underscores the importance of innovative educational tools in advancing scientific research and fostering collaboration between academia and industry.

Organs-On-Chips Market, By Application

• Drug Discovery
• Toxicology Research
• Physiological Model
• Others

Based on the Application, the Global Organs-On-Chips Market is segmented into Drug Discovery, Toxicology Research, Physiological Model, and Others. In the organs-on-chips market, the drug discovery segment is currently the dominant application, as it plays a crucial role in streamlining the drug development process and improving success rates. However, the toxicology research segment is experiencing rapid growth, driven by the increasing need for safer and more effective testing methods that reduce reliance on animal models. This shift reflects a broader trend toward regulatory compliance and ethical considerations in biomedical research.

Organs-On-Chips Market, By Type

• Heart on chip
• Human on chip
• Intestine on chip
• Kidney on chip
• Liver on chip
• Lung on chip

Based on Type, the Global Organs-On-Chips Market is segmented into Heart on chip, Human on chip, Intestine on chip, Kidney on chip, Liver on chip, and Lung on chip. In the organs-on-chips market, the liver on chip segment is currently dominating, driven by its critical role in drug metabolism and toxicity testing. However, the heart on chip segment is rapidly growing, fueled by increasing interest in cardiovascular disease research and personalized medicine applications. This trend highlights the rising demand for innovative models that can replicate complex organ functions for more accurate drug testing and development.

Organs-On-Chips Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Organs-On-Chips Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. In the organs-on-chips market, North America currently dominates due to its robust biotechnology sector and significant investments in research and development. However, the Asia Pacific region is emerging rapidly, driven by increasing government support for advanced biomedical technologies and a growing emphasis on personalized medicine. This shift indicates a strong potential for growth in Asia Pacific as it invests in innovative healthcare solutions.

Key Players

• The "Global Organs-On-Chips Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• BiomimX SRL, Elveflow, Hesperos, Altis Biosystems, Nortis, Inc., AxoSim, Bi/ond, InSphero, Emulate, Inc., Allevi, Inc., MIMETAS BV, Netri, Valo Health (Tara Biosystems, Inc.), TissUse GmbH., MesoBiotech, Chiron, Cherry Biotech, 4Dcell, BioIVT, AlveoliX, BEOnchip, Tissue Dynamics.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Organs-On-Chips Market Key Developments

• In August 2023, Emulate, Inc. announced the launch of its next-generation organ-on-chip platform, which offers enhanced predictive capabilities for drug response and toxicity testing, promising to accelerate drug development timelines.
• In July 2023, researchers at MIT unveiled a novel multi-organ chip system that simulates human organ interactions more accurately, paving the way for improved disease modeling and personalized medicine applications.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ORGANS-ON-CHIPS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources
• 3.5 Market attractiveness

4 GLOBAL ORGANS-ON-CHIPS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL ORGANS-ON-CHIPS MARKET, BY TYPE

• 5.1 Heart on chip
• 5.2 Human on chip
• 5.3 Intestine on chip
• 5.4 Kidney on chip
• 5.5 Liver on chip
• 5.6 Lung on chip

6 GLOBAL ORGANS-ON-CHIPS MARKET, BY APPLICATION

• 6.1 Drug discovery
• 6.2 Toxicology research
• 6.3 Physiological Model
• 6.4 Other applications

7 GLOBAL ORGANS-ON-CHIPS MARKET, BY END USER

• 7.1 Pharmaceutical and biotechnology companies
• 7.2 Academic
• 7.3 Research institutes

8 GLOBAL ORGANS-ON-CHIPS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL ORGANS-ON-CHIPS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies
• 9.4 ACE Matrix

10 COMPANY PROFILES

• 10.1 BiomimX SRL
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Elveflow
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Hesperos
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Altis Biosystems
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Nortis Inc.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 AxoSim
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Development
• 10.7 Bi/ond
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 InSphero
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Development
• 10.9 Emulate Inc.
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
• 10.10 Allevi Inc.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
• 10.11 MIMETAS BV
  • 10.11.1 Overview
  • 10.11.2 Financial Performance
  • 10.11.3 Product Outlook
• 10.12 Netri
  • 10.12.1 Overview
  • 10.12.2 Financial Performance
  • 10.12.3 Product Outlook
• 10.13 Valo Health (Tara Biosystems Inc.)
  • 10.13.1 Overview
  • 10.13.2 Financial Performance
  • 10.13.3 Product Outlook
• 10.14 TissUse GmbH
  • 10.14.1 Overview
  • 10.14.2 Financial Performance
  • 10.14.3 Product Outlook

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research